Compare JF & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JF | SCNX |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | China | United States |
| Employees | 30 | N/A |
| Industry | | Other Pharmaceuticals |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 16.2M |
| IPO Year | 2017 | 2019 |
| Metric | JF | SCNX |
|---|---|---|
| Price | $0.91 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 7.8K | ★ 622.6K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $0.81 | $0.24 |
| 52 Week High | $1.19 | $2.60 |
| Indicator | JF | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 38.44 | 20.94 |
| Support Level | $0.90 | $0.24 |
| Resistance Level | $1.03 | $0.43 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 0.00 | 4.64 |
J and Friends Holdings Ltd providing merchant digitalization and commerce-enablement solutions to small and medium enterprises (SME). Its solutions feature critical functionality that SMEs need to engage with consumers, manage their operations, accept payments, and grow their business. Such solutions empower single- and multi-location retailers, restaurants, and other SMEs to compete successfully in an omni-channel market environment by engaging with consumers across online, mobile, and physical channels. The group conducts all of its current operations in Australia and generates revenues from continuing operations are derived from within Australia.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.